Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 273 articles: HTML format

Single Articles

July 2021
1. GOMEZ TEJEDA ZANUDO J, Mao P, Alcon C, Kowalski K, et al
   Cell line-specific network models of ER+ breast cancer identify potential PI3Kalpha inhibitor resistance mechanisms and drug combinations.
   Cancer Res. 2021 Jul 13. pii: 0008-5472.CAN-21-1208.
   PubMed     Abstract available
   
   
   June 2021
2. LAINE A, Nagelli SG, Farrington C, Butt U, et al
   CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis.
   Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3651.
   PubMed     Abstract available
   
   
   
3. CANO A, Lopez-Menendez C, Vazquez-Naharro A, Santos V, et al
   E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer.
   Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-2685.
   PubMed     Abstract available
   
   
   
4. SHARIF GM, Campbell MJ, Nasir A, Sengupta S, et al
   An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer.
   Cancer Res. 2021 Jun 16. pii: 0008-5472.CAN-20-3625.
   PubMed     Abstract available
   
   
   
5. 
   Correction: Cyclophosphamide and Vinorelbine Activate Stem-Like CD8(+) T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer.
   Cancer Res. 2021;81:3426.
   PubMed    
   
   
   
6. HARRIS RJ, Cheung A, Ng JCF, Laddach R, et al
   Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes In Triple-Negative Breast Cancer.
   Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-20-3773.
   PubMed     Abstract available
   
   
   
7. WANG T, Farvid MS, Kang JH, Holmes MD, et al
   Diabetes Risk Reduction Diet and Survival After Breast Cancer Diagnosis.
   Cancer Res. 2021 Jun 9. pii: 0008-5472.CAN-21-0256.
   PubMed     Abstract available
   
   
   
8. ZHANG H, Zhang N, Liu Y, Su P, et al
   Correction: Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
   Cancer Res. 2021;81:3145.
   PubMed    
   
   
   
9. YUZEFOVYCH LV, Kahn AG, Schuler MA, Eide L, et al
   Correction: Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis.
   Cancer Res. 2021;81:3144.
   PubMed    
   
   
   May 2021
10. SHAN P, Yang F, Qi H, Hu Y, et al
    Alteration of MDM2 by the small molecule YF438 exerts anti-tumor effects in triple-negative breast cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-0922.
    PubMed     Abstract available
    
    
    
11. HAPACH LA, Carey SP, Schwager SC, Taufalele PV, et al
    Phenotypic heterogeneity and metastasis of breast cancer cells.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-1799.
    PubMed     Abstract available
    
    
    
12. GUO Q, Bartish M, Goncalves C, Huang F, et al
    The MNK1/2-eIF4E axis supports immune suppression and metastasis in postpartum breast cancer.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-3143.
    PubMed     Abstract available
    
    
    April 2021
13. SHARMA D
    Towards Taming the Bugs to Improve the Drugs for Breast Cancer.
    Cancer Res. 2021;81:1937-1939.
    PubMed     Abstract available
    
    
    
14. CHEN F, Chen Z, Guan T, Zhou Y, et al
    N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-3779.
    PubMed     Abstract available
    
    
    March 2021
15. LI CI, Flanagan MR, Tang MC, Porter PL, et al
    Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma In Situ.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-4100.
    PubMed     Abstract available
    
    
    
16. HU L, Su L, Cheng H, Mo C, et al
    Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers.
    Cancer Res. 2021 Mar 16. pii: 0008-5472.CAN-20-2123.
    PubMed     Abstract available
    
    
    
17. CARVAJAL-MALDONADO D, Wood RD
    Regulating Poltheta in Breast Cancer.
    Cancer Res. 2021;81:1441-1442.
    PubMed     Abstract available
    
    
    
18. PRODHOMME MK, Pommier RM, Franchet C, Fauvet F, et al
    EMT Transcription Factor ZEB1 Represses the Mutagenic POLtheta-Mediated End-Joining Pathway in Breast Cancers.
    Cancer Res. 2021;81:1595-1606.
    PubMed     Abstract available
    
    
    
19. HAN YJ, Zhang J, Lee JH, Mason JM, et al
    The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.
    Cancer Res. 2021;81:1540-1551.
    PubMed     Abstract available
    
    
    
20. TERVONEN TA, Pant SM, Belitskin D, Englund JI, et al
    Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
    Cancer Res. 2021;81:1513-1527.
    PubMed     Abstract available
    
    
    
21. ZHOU Y, Jin X, Ma J, Ding D, et al
    HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Cancer Res. 2021;81:1486-1499.
    PubMed     Abstract available
    
    
    
22. CAI Y, Xu G, Wu F, Michelini F, et al
    Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kalpha inhibitors.
    Cancer Res. 2021 Mar 8. pii: 0008-5472.CAN-20-3232.
    PubMed     Abstract available
    
    
    
23. DAI M, Boudreault J, Wang N, Poulet S, et al
    Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
    Cancer Res. 2021;81:1332-1346.
    PubMed     Abstract available
    
    
    
24. KUMARASAMY V, Vail P, Nambiar R, Witkiewicz AK, et al
    Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
    Cancer Res. 2021;81:1347-1360.
    PubMed     Abstract available
    
    
    February 2021
25. YU R, Longo J, van Leeuwen JE, Zhang C, et al
    Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching.
    Cancer Res. 2021 Feb 18. pii: 0008-5472.CAN-20-2642.
    PubMed     Abstract available
    
    
    
26. LEE S, Amgad M, Mobadersany P, McCormick M, et al
    Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers.
    Cancer Res. 2021;81:1171-1177.
    PubMed     Abstract available
    
    
    
27. QUINN HM, Vogel R, Popp O, Mertins P, et al
    YAP and beta-catenin cooperate to drive oncogenesis in basal breast cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2801.
    PubMed     Abstract available
    
    
    
28. SINGH S, Sutcliffe MD, Repich K, Atkins KA, et al
    Pan-cancer Drivers are Recurrent Transcriptional Regulatory Heterogeneities in Early-stage Luminal Breast Cancer.
    Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-1034.
    PubMed     Abstract available
    
    
    
29. WYSS CB, Duffey N, Peyvandi S, Barras D, et al
    Gain of HIF1 Activity and Loss of miRNA let-7d Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis.
    Cancer Res. 2021;81:594-605.
    PubMed     Abstract available
    
    
    
30. PARDINI B, Dragomir MP
    SCIRT lncRNA Blocks the Shot of Breast Cancer Cells Self-Renewal Mechanism.
    Cancer Res. 2021;81:535-536.
    PubMed     Abstract available
    
    
    
31. HERMIDA-PRADO F, Jeselsohn R
    The ESR1 Mutations: From Bedside to Bench to Bedside.
    Cancer Res. 2021;81:537-538.
    PubMed     Abstract available
    
    
    
32. CRESSWELL GM, Wang B, Kischuk EM, Broman MM, et al
    Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cancer Res. 2021;81:671-684.
    PubMed     Abstract available
    
    
    
33. ZAGORAC S, de Giorgio A, Dabrowska A, Kalisz M, et al
    SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells.
    Cancer Res. 2021;81:580-593.
    PubMed     Abstract available
    
    
    January 2021
34. THOMAS C, Karagounis IV, Srivastava RK, Vrettos N, et al
    Estrogen receptor beta-mediated inhibition of actin-based cell migration suppresses metastasis of inflammatory breast cancer.
    Cancer Res. 2021 Jan 29. pii: 0008-5472.CAN-20-2743.
    PubMed     Abstract available
    
    
    
35. PECK B, Bland P, Mavrommati I, Muirhead G, et al
    3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
    Cancer Res. 2021 Jan 28. pii: 0008-5472.CAN-20-1822.
    PubMed     Abstract available
    
    
    
36. SANDIFORD OA, Donnelly RJ, El-Far M, Burgmeyer LM, et al
    Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region.
    Cancer Res. 2021 Jan 26. pii: 0008-5472.CAN-20-2434.
    PubMed     Abstract available
    
    
    
37. BARNABAS GD, Sang Lee J, Shami T, Harel M, et al
    Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
    Cancer Res. 2021 Jan 26. pii: 0008-5472.CAN-19-3020.
    PubMed     Abstract available
    
    
    
38. DI MODICA M, Gargari G, Regondi V, Bonizzi A, et al
    Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer.
    Cancer Res. 2021 Jan 22. pii: 0008-5472.CAN-20-1659.
    PubMed     Abstract available
    
    
    
39. MESTRE-FARRERA A, Bruch-Oms M, Pena R, Rodriguez-Morato J, et al
    Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion.
    Cancer Res. 2021;81:438-451.
    PubMed     Abstract available
    
    
    
40. KOLAPALLI SP, Sahu R, Chauhan NR, Jena KK, et al
    RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression.
    Cancer Res. 2021;81:315-331.
    PubMed     Abstract available
    
    
    
41. DHIMOLEA E, de Matos Simoes R, Kansara D, Weng X, et al
    Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Cancer Res. 2021;81:371-383.
    PubMed     Abstract available
    
    
    
42. XING F, Zhao D, Wu SY, Tyagi A, et al
    Epigenetic and post-transcriptional modulation of SOS1 can promote breast cancer metastasis through obesity-activated c-Met signaling in African American women.
    Cancer Res. 2021 Jan 14. pii: 0008-5472.CAN-19-4031.
    PubMed     Abstract available
    
    
    
43. MILLER KD, Pniewski K, Perry CE, Papp SB, et al
    Targeting ACSS2 with a transition state mimetic inhibits triple-negative breast cancer growth.
    Cancer Res. 2021 Jan 7. pii: 0008-5472.CAN-20-1847.
    PubMed     Abstract available
    
    
    
44. LIU Z, Sun L, Cai Y, Shen S, et al
    Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1.
    Cancer Res. 2021 Jan 5. pii: 0008-5472.CAN-20-2876.
    PubMed     Abstract available
    
    
    
45. JEONG GY, Park MK, Choi HJ, An HW, et al
    NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
    Cancer Res. 2021;81:77-90.
    PubMed     Abstract available
    
    
    December 2020
46. KARLSSON T, Johansson T, Hoglund J, Ek WE, et al
    Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers.
    Cancer Res. 2020 Dec 17. pii: 0008-5472.CAN-20-2476.
    PubMed     Abstract available
    
    
    
47. ZHENG W, Ranoa DRE, Huang X, Hou Y, et al
    RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy.
    Cancer Res. 2020;80:5633-5641.
    PubMed     Abstract available
    
    
    
48. WANG F, Zheng W, Bailey CE, Mayer IA, et al
    Racial/Ethnic Disparities in All-Cause Mortality Among Patients Diagnosed with Triple-Negative Breast Cancer.
    Cancer Res. 2020 Dec 3. pii: 0008-5472.CAN-20-3094.
    PubMed     Abstract available
    
    
    
49. FALVO P, Orecchioni S, Hillje R, Raveane A, et al
    Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer.
    Cancer Res. 2020 Dec 2. pii: 0008-5472.CAN-20-1818.
    PubMed     Abstract available
    
    
    
50. MIAR A, Arnaiz E, Bridges E, Beedie S, et al
    Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types.
    Cancer Res. 2020;80:5245-5256.
    PubMed     Abstract available
    
    
    
51. HEASTER TM, Humayun M, Yu J, Beebe DJ, et al
    Autofluorescence Imaging of 3D Tumor-Macrophage Microscale Cultures Resolves Spatial and Temporal Dynamics of Macrophage Metabolism.
    Cancer Res. 2020;80:5408-5423.
    PubMed     Abstract available
    
    
    
52. LIAPIS E, Klemm U, Karlas A, Reber J, et al
    Resolution of Spatial and Temporal Heterogeneity in Bevacizumab-Treated Breast Tumors by Eigenspectra Multispectral Optoacoustic Tomography.
    Cancer Res. 2020;80:5291-5304.
    PubMed     Abstract available
    
    
    November 2020
53. DAVRA V, Kumar S, Geng K, Calianese D, et al
    Axl and Mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host anti-tumor immunity.
    Cancer Res. 2020 Nov 25. pii: 0008-5472.CAN-20-2066.
    PubMed     Abstract available
    
    
    
54. FARVID MS, Holmes MD, Chen WY, Rosner BA, et al
    Postdiagnostic Fruit and Vegetable Consumption and Breast Cancer Survival: Prospective Analyses in the Nurses' Health Studies.
    Cancer Res. 2020;80:5134-5143.
    PubMed     Abstract available
    
    
    
55. MAMO M, Ye IC, DiGiacomo JW, Park JY, et al
    Hypoxia Alters the Response to Anti-EGFR Therapy by Regulating EGFR Expression and Downstream Signaling in a DNA Methylation-Specific and HIF-Dependent Manner.
    Cancer Res. 2020;80:4998-5010.
    PubMed     Abstract available
    
    
    
56. SOOTOME H, Fujita H, Ito K, Ochiiwa H, et al
    Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Cancer Res. 2020;80:4986-4997.
    PubMed     Abstract available
    
    
    
57. KIMMEL GJ, Dane M, Heiser LM, Altrock PM, et al
    Integrating Mathematical Modeling with High-Throughput Imaging Explains How Polyploid Populations Behave in Nutrient-Sparse Environments.
    Cancer Res. 2020;80:5109-5120.
    PubMed     Abstract available
    
    
    
58. LAUKO A, Mu Z, Gutmann DH, Naik UP, et al
    Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell-Cell Interactions in Tumor Progression.
    Cancer Res. 2020;80:4878-4885.
    PubMed     Abstract available
    
    
    
59. ARNESEN S, Blanchard Z, Williams MM, Berrett KC, et al
    Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects.
    Cancer Res. 2020 Nov 12. pii: 0008-5472.CAN-20-1171.
    PubMed     Abstract available
    
    
    
60. WILLIAMS MM, Spoelstra NS, Arnesen S, O'Neill KI, et al
    Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1 mutant breast cancer.
    Cancer Res. 2020 Nov 12. pii: 0008-5472.CAN-20-1200.
    PubMed     Abstract available
    
    
    
61. CHEN F, Ding K, Priedigkeit N, Elangovan A, et al
    Single-cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells.
    Cancer Res. 2020 Nov 4. pii: 0008-5472.CAN-20-0696.
    PubMed     Abstract available
    
    
    
62. WANG Y, Luo M, Chen Y, Wang Y, et al
    ZMYND8 expression in breast cancer cells blocks T-lymphocyte surveillance to promote tumor growth.
    Cancer Res. 2020 Nov 4. pii: 0008-5472.CAN-20-1710.
    PubMed     Abstract available
    
    
    October 2020
63. CRUMP LS, Wyatt G, Rutherford TR, Richer JK, et al
    Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance.
    Cancer Res. 2020 Oct 29. pii: 0008-5472.CAN-20-1601.
    PubMed     Abstract available
    
    
    
64. WILLS CA, Liu X, Chen L, Zhao Y, et al
    Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1976.
    PubMed     Abstract available
    
    
    
65. OGRODZINSKI MP, Teoh ST, Lunt SY
    Targeting subtype-specific metabolic preferences in nucleotide biosynthesis inhibits tumor growth in a breast cancer model.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1666.
    PubMed     Abstract available
    
    
    
66. SMALLEY M, Natarajan SK, Mondal J, Goldman D, et al
    Nano-Engineered Disruption of Heat shock protein 90 (Hsp90) Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer.
    Cancer Res. 2020 Oct 19. pii: 0008-5472.CAN-19-4036.
    PubMed     Abstract available
    
    
    
67. CHAMBERLIN T, Clack M, Silvers C, Kuziel G, et al
    Targeting Obesity-Induced Macrophages during Preneoplastic Growth Promotes Mammary Epithelial Stem/Progenitor Activity, DNA Damage, and Tumor Formation.
    Cancer Res. 2020;80:4465-4475.
    PubMed     Abstract available
    
    
    
68. BLANCO-GOMEZ A, Hontecillas-Prieto L, Corchado-Cobos R, Garcia-Sancha N, et al
    Stromal SNAI2 is required for ERBB2 breast cancer progression.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-20-0278.
    PubMed     Abstract available
    
    
    
69. SHANI O, Vorobyov T, Monteran L, Lavie D, et al
    Fibroblast-derived IL-33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type-2 immunity.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-20-2116.
    PubMed     Abstract available
    
    
    
70. DWANE L, O'Connor AE, Das S, Moran B, et al
    A functional genomic screen identifies the deubiquitinase USP11 as a novel transcriptional regulator of ERalpha in breast cancer.
    Cancer Res. 2020 Oct 1. pii: 0008-5472.CAN-20-0214.
    PubMed     Abstract available
    
    
    
71. PARK D, Bergin SM, Jones D, Ru P, et al
    Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
    Cancer Res. 2020;80:4172-4184.
    PubMed     Abstract available
    
    
    
72. ANLAS AA, Nelson CM
    Soft Microenvironments Induce Chemoresistance by Increasing Autophagy Downstream of Integrin-Linked Kinase.
    Cancer Res. 2020;80:4103-4113.
    PubMed     Abstract available
    
    
    
73. YANG C, Wu J, Liu X, Wang Y, et al
    Circadian Rhythm Is Disrupted by ZNF704 in Breast Carcinogenesis.
    Cancer Res. 2020;80:4114-4128.
    PubMed     Abstract available
    
    
    September 2020
74. BOLKESTEIN M, Wong JKL, Thewes V, Korber V, et al
    Chromothripsis in human breast cancer.
    Cancer Res. 2020 Sep 24. pii: 0008-5472.CAN-20-1920.
    PubMed     Abstract available
    
    
    
75. BHAT-NAKSHATRI P, Kumar B, Simpson E, Ludwig KK, et al
    Breast cancer cell detection and characterization from breast milk-derived cells.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-1030.
    PubMed     Abstract available
    
    
    
76. MAHAUAD-FERNANDEZ WD, Felsher DW
    The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
    Cancer Res. 2020;80:3799-3802.
    PubMed     Abstract available
    
    
    
77. GHERGUROVICH JM, Esposito M, Chen Z, Wang JZ, et al
    Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras-Driven Tumor Growth or Metastasis.
    Cancer Res. 2020;80:3820-3829.
    PubMed     Abstract available
    
    
    
78. WESTCOTT JM, Camacho S, Nasir A, Huysman ME, et al
    DeltaNp63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion.
    Cancer Res. 2020;80:3933-3944.
    PubMed     Abstract available
    
    
    
79. HUANG M, O'Shaughnessy J, Zhao J, Haiderali A, et al
    Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis.
    Cancer Res. 2020 Sep 14. pii: 0008-5472.CAN-20-1792.
    PubMed     Abstract available
    
    
    
80. TUBEUF H, Caputo SM, Sullivan T, Rondeaux J, et al
    Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.
    Cancer Res. 2020;80:3593-3605.
    PubMed     Abstract available
    
    
    August 2020
81. PRZANOWSKI P, Lou S, Tihagam RD, Mondal T, et al
    Oncogenic TRIM37 links chemoresistance and metastatic fate in triple-negative breast cancer.
    Cancer Res. 2020 Aug 27. pii: 0008-5472.CAN-20-1459.
    PubMed     Abstract available
    
    
    
82. ABRAHAMSSON A, Vazquez Rodriguez G, Dabrosin C
    Fulvestrant-mediated attenuation of the innate immune response decreases ER+ breast cancer growth in vivo more effectively than tamoxifen.
    Cancer Res. 2020 Aug 27. pii: 0008-5472.CAN-20-1705.
    PubMed     Abstract available
    
    
    
83. FANG Z, Wang Y, Wang Z, Xu M, et al
    ERINA is an estrogen-responsive lncRNA that drives breast cancer through the E2F1/RB1 pathway.
    Cancer Res. 2020 Aug 21. pii: 0008-5472.CAN-20-1031.
    PubMed     Abstract available
    
    
    
84. CONWAY ME, McDaniel JM, Graham JM, Guillen KP, et al
    STAT3 and GR cooperate to drive gene expression and growth of basal-like triple-negative breast cancer.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-1379.
    PubMed     Abstract available
    
    
    
85. IRURZUN-ARANA I, McDonald TO, Troconiz IF, Michor F, et al
    Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
    Cancer Res. 2020;80:3372-3382.
    PubMed     Abstract available
    
    
    
86. AMBROSONE CB, Higgins MJ
    Relationships between breast feeding and breast cancer subtypes: lessons learned from studies in humans and in mice.
    Cancer Res. 2020 Aug 14. pii: 0008-5472.CAN-20-0077.
    PubMed     Abstract available
    
    
    
87. VERRET B, Sourisseau T, Stefanovska B, Mosele F, et al
    The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.
    Cancer Res. 2020;80:3062-3069.
    PubMed     Abstract available
    
    
    July 2020
88. DATTILO R, Mottini C, Camera E, Lamolinara A, et al
    Pyrvinium pamoate induces death of triple-negative breast cancer stem-like cells and reduces metastases through effects on lipid anabolism.
    Cancer Res. 2020 Jul 23. pii: 0008-5472.CAN-19-1184.
    PubMed     Abstract available
    
    
    
89. WANG Y, Chen Y, Bao L, Zhang B, et al
    CHD4 promotes breast cancer progression as a coactivator of hypoxia-inducible factors.
    Cancer Res. 2020 Jul 22. pii: 0008-5472.CAN-20-1049.
    PubMed     Abstract available
    
    
    
90. CAI C
    A Novel Mechanism to Induce BRCAness in Cancer Cells.
    Cancer Res. 2020;80:2977-2978.
    PubMed     Abstract available
    
    
    
91. SILVESTRI VL, Henriet E, Linville RM, Wong AD, et al
    A tissue-engineered 3D microvessel model reveals the dynamics of mosaic vessel formation in breast cancer.
    Cancer Res. 2020 Jul 14. pii: 0008-5472.CAN-19-1564.
    PubMed     Abstract available
    
    
    
92. BRIDGES AE, Ramachandran S, Pathania R, Parwal U, et al
    RAD51AP1 deficiency reduces tumor growth by targeting stem cell self-renewal.
    Cancer Res. 2020 Jul 14. pii: 0008-5472.CAN-19-3713.
    PubMed     Abstract available
    
    
    
93. DAI C, Charlestin V, Wang M, Walker ZT, et al
    Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer.
    Cancer Res. 2020 Jul 6. pii: 0008-5472.CAN-19-2269.
    PubMed     Abstract available
    
    
    
94. CHAO JT, Hollman R, Meyers WM, Meili F, et al
    A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants.
    Cancer Res. 2020;80:2775-2789.
    PubMed     Abstract available
    
    
    
95. BOUCHET M, Laine A, Boyault C, Proponnet-Guerault M, et al
    ERRalpha Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response.
    Cancer Res. 2020;80:2914-2926.
    PubMed     Abstract available
    
    
    
96. QUINTANA E, Schulze CJ, Myers DR, Choy TJ, et al
    Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Cancer Res. 2020;80:2889-2902.
    PubMed     Abstract available
    
    
    
97. BUI NHB, Napoli M, Davis AJ, Abbas HA, et al
    Spatiotemporal Regulation of DeltaNp63 by TGFbeta-Regulated miRNAs Is Essential for Cancer Metastasis.
    Cancer Res. 2020;80:2833-2847.
    PubMed     Abstract available
    
    
    June 2020
98. BANIK D, Noonepalle S, Hadley M, Palmer E, et al
    HDAC6 plays a non-canonical role in the regulation of anti-tumor immune responses, dissemination, and invasiveness of breast cancer.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-19-3738.
    PubMed     Abstract available
    
    
    
99. SAXENA M, Kalathur RKR, Rubinstein N, Vettiger A, et al
    A Pygopus 2-histone interaction is critical for cancer cell de-differentiation and progression in malignant breast cancer.
    Cancer Res. 2020 Jun 25. pii: 0008-5472.CAN-19-2910.
    PubMed     Abstract available
    
    
    
100. ZHOU H, Blevins MA, Hsu JY, Kong D, et al
     Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.
     Cancer Res. 2020;80:2689-2702.
     PubMed     Abstract available
     
     
     
101. VASIUKOV G, Novitskaya T, Zijlstra A, Owens P, et al
     Myeloid Cell-Derived TGFbeta Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.
     Cancer Res. 2020;80:2628-2638.
     PubMed     Abstract available
     
     
     
102. ZHOU Z, Zhou H, Ponzoni L, Luo A, et al
     EIF3H Orchestrates Hippo Pathway-Mediated Oncogenesis via Catalytic Control of YAP Stability.
     Cancer Res. 2020;80:2550-2563.
     PubMed     Abstract available
     
     
     
103. SUN L, Li CW, Chung EM, Yang R, et al
     Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
     Cancer Res. 2020;80:2298-2310.
     PubMed     Abstract available
     
     
     May 2020
104. TROTTER TN, Shuptrine CW, Tsao LC, Marek RD, et al
     IL-26, a non-canonical mediator of DNA inflammatory stimulation, promotes TNBC engraftment and progression in association with neutrophils.
     Cancer Res. 2020 May 4. pii: 0008-5472.CAN-18-3825.
     PubMed     Abstract available
     
     
     April 2020
105. THIES KA, Hammer AM, Hildreth BE, Steck SA, et al
     Stromal platelet-derived growth factor receptor-beta signaling promotes breast cancer metastasis in the brain.
     Cancer Res. 2020 Apr 23. pii: 0008-5472.CAN-19-3731.
     PubMed     Abstract available
     
     
     
106. CHU W, Zhang X, Qi L, Fu Y, et al
     The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer.
     Cancer Res. 2020 Apr 20. pii: 0008-5472.CAN-19-3326.
     PubMed     Abstract available
     
     
     
107. KENNEDY KM, Zilkens R, Allen WM, Foo KY, et al
     Diagnostic Accuracy of Quantitative Micro-Elastography for Margin Assessment in Breast-Conserving Surgery.
     Cancer Res. 2020;80:1773-1783.
     PubMed     Abstract available
     
     
     
108. VANNA R, Morasso C, Marcinno B, Piccotti F, et al
     Raman Spectroscopy Reveals That Biochemical Composition of Breast Microcalcifications Correlates with Histopathologic Features.
     Cancer Res. 2020;80:1762-1772.
     PubMed     Abstract available
     
     
     
109. ROBERTS MS, Sahni JM, Schrock MS, Piemonte KM, et al
     LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
     Cancer Res. 2020;80:1693-1706.
     PubMed     Abstract available
     
     
     
110. PEDERSEN L, Panahandeh P, Siraji MI, Knappskog S, et al
     Golgi-localized PAQR4 mediates Anti-apoptotic Ceramidase Activity in Breast Cancer.
     Cancer Res. 2020 Apr 14. pii: 0008-5472.CAN-19-3177.
     PubMed     Abstract available
     
     
     
111. MOSHKOVICH N, Ochoa HJ, Tang B, Yang HH, et al
     Peptidylarginine deiminase IV (PADI4) regulates breast cancer stem cells via a novel tumor cell-autonomous suppressor role.
     Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-3018.
     PubMed     Abstract available
     
     
     
112. YANG L, So JY, Skrypek N, Yang HH, et al
     Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization.
     Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-3339.
     PubMed     Abstract available
     
     
     
113. HARNOSS JM, Le Thomas A, Reichelt M, Guttman O, et al
     IRE1alpha disruption in triple-negative breast cancer cooperates with anti-angiogenic therapy by reversing ER stress adaptation and remodeling the tumor microenvironment.
     Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-3108.
     PubMed     Abstract available
     
     
     
114. MARKER KM, Zavala VA, Vidaurre T, Lott PC, et al
     Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.
     Cancer Res. 2020 Apr 3. pii: 0008-5472.CAN-19-3659.
     PubMed     Abstract available
     
     
     
115. HOLOWKO N, Eriksson M, Kuja-Halkola R, Azam S, et al
     Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses.
     Cancer Res. 2020;80:1590-1600.
     PubMed     Abstract available
     
     
     
116. SCHIPPER K, Drenth AP, van der Burg E, Cornelissen S, et al
     Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.
     Cancer Res. 2020;80:1486-1497.
     PubMed     Abstract available
     
     
     
117. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
     Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
     Cancer Res. 2020;80:1374-1386.
     PubMed     Abstract available
     
     
     
118. QIAO X, Liu Y, Prada ML, Mohan AK, et al
     UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis.
     Cancer Res. 2020;80:1414-1427.
     PubMed     Abstract available
     
     
     March 2020
119. MITOBE Y, Iino K, Takayama KI, Ikeda K, et al
     PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2.
     Cancer Res. 2020 Mar 25. pii: 0008-5472.CAN-19-3095.
     PubMed     Abstract available
     
     
     
120. ZHAO Y, Kaushik N, Kang JH, Kaushik NK, et al
     A Feedback loop comprising EGF/TGF-alpha Sustains TFCP2-mediated Breast Cancer Progression.
     Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-2908.
     PubMed     Abstract available
     
     
     
121. FLACH KD, Periyasamy M, Jadhav A, Dorjsuren D, et al
     Endonuclease FEN1 coregulates ERalpha activity and provides a novel drug interface in tamoxifen resistant breast cancer.
     Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-2207.
     PubMed     Abstract available
     
     
     
122. LUO ML, Zheng F, Chen W, Liang ZM, et al
     Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
     Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-2739.
     PubMed     Abstract available
     
     
     
123. MAJORINI MT, Cancila V, Rigoni A, Botti L, et al
     Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype.
     Cancer Res. 2020 Mar 16. pii: 0008-5472.CAN-19-3596.
     PubMed     Abstract available
     
     
     
124. SAMI E, Paul BT, Koziol JA, ElShamy WM, et al
     The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
     Cancer Res. 2020;80:1102-1117.
     PubMed     Abstract available
     
     
     
125. KARKI K, Wright GA, Mohankumar K, Jin UH, et al
     A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
     Cancer Res. 2020;80:1011-1023.
     PubMed     Abstract available
     
     
     
126. BRINKER AE, Vivian CJ, Beadnell TC, Koestler DC, et al
     Mitochondrial Haplotype of the Host Stromal Microenvironment Alters Metastasis in a Non-cell Autonomous Manner.
     Cancer Res. 2020;80:1118-1129.
     PubMed     Abstract available
     
     
     February 2020
127. BORGES VF, Lyons TR, Germain D, Schedin P, et al
     Postpartum involution and cancer: an opportunity for targeted breast cancer prevention and treatments?
     Cancer Res. 2020 Feb 19. pii: 0008-5472.CAN-19-3448.
     PubMed     Abstract available
     
     
     
128. BERI P, Popravko A, Yeoman B, Kumar A, et al
     Cell Adhesiveness Serves as a Biophysical Marker for Metastatic Potential.
     Cancer Res. 2020;80:901-911.
     PubMed     Abstract available
     
     
     
129. KARIMIAN A, Ji NT, Song H, Sgouros G, et al
     Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.
     Cancer Res. 2020;80:868-876.
     PubMed     Abstract available
     
     
     
130. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
     Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
     Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
     PubMed     Abstract available
     
     
     
131. MALLETER M, Tauzin S, Bessede A, Castellano R, et al
     Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer.
     Cancer Res. 2020;80:639.
     PubMed    
     
     
     
132. KONG T, Ahn R, Yang K, Zhu X, et al
     CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
     Cancer Res. 2020;80:444-457.
     PubMed     Abstract available
     
     
     
133. GALE M, Li Y, Cao J, Liu ZZ, et al
     Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.
     Cancer Res. 2020;80:524-535.
     PubMed     Abstract available
     
     
     January 2020
134. JANG JH, Kim DH, Lim JM, Lee JW, et al
     Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL-1beta production.
     Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2288.
     PubMed     Abstract available
     
     
     
135. ECKHARDT BL, Cao Y, Redfern AD, Chi LH, et al
     Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis.
     Cancer Res. 2020 Jan 15. pii: 0008-5472.CAN-19-0743.
     PubMed     Abstract available
     
     
     
136. BUNZ F
     EMT and Back Again: Visualizing the Dynamic Phenotypes of Metastasis.
     Cancer Res. 2020;80:153-155.
     PubMed     Abstract available
     
     
     
137. GEORGESS D, Padmanaban V, Sirka OK, Coutinho K, et al
     Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling.
     Cancer Res. 2020;80:204-218.
     PubMed     Abstract available
     
     
     
138. LOH XY, Sun QY, Ding LW, Mayakonda A, et al
     RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling.
     Cancer Res. 2020;80:219-233.
     PubMed     Abstract available
     
     
     
139. SANTORO AL, Drummond RD, da Silva IT, Ferreira SS, et al
     In situ DESI - MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions.
     Cancer Res. 2020 Jan 7. pii: 0008-5472.CAN-18-3574.
     PubMed     Abstract available
     
     
     
140. SANCHEZ-GONZALEZ I, Bobien A, Molnar C, Schmid S, et al
     miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages.
     Cancer Res. 2020 Jan 7. pii: 0008-5472.CAN-19-1934.
     PubMed     Abstract available
     
     
     
141. NIU Y, Bao L, Chen Y, Wang C, et al
     HIF-2-induced long non-coding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis.
     Cancer Res. 2020 Jan 3. pii: 0008-5472.CAN-19-1532.
     PubMed     Abstract available
     
     
     
142. NIEHOFF NM, White AJ, Sandler DP
     Physical Activity and Breast Cancer: Focusing on High-Risk Subgroups and Putting Recommendations in Context.
     Cancer Res. 2020;80:23-24.
     PubMed     Abstract available
     
     
     
143. FLETCHER A, Read ML, Thornton CEM, Larner DP, et al
     Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
     Cancer Res. 2020;80:102-115.
     PubMed     Abstract available
     
     
     December 2019
144. CITRON F, Segatto I, Rampioni Vinciguerra GL, Musco L, et al
     Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer.
     Cancer Res. 2019 Dec 20. pii: 0008-5472.CAN-19-1793.
     PubMed     Abstract available
     
     
     
145. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
     Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
     Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
     PubMed     Abstract available
     
     
     November 2019
146. XIAO G, Lundine D, Annor GK, Canar J, et al
     Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
     Cancer Res. 2019 Nov 27. pii: 0008-5472.CAN-19-1036.
     PubMed     Abstract available
     
     
     
147. CHIODONI C, Cancila V, Renzi TA, Perrone M, et al
     Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs.
     Cancer Res. 2019 Nov 27. pii: 0008-5472.CAN-19-1425.
     PubMed     Abstract available
     
     
     
148. CHEN R, Goodison S, Sun Y
     Molecular profiles of matched primary and metastatic tumor samples support a linear evolutionary model of breast cancer.
     Cancer Res. 2019 Nov 19. pii: 0008-5472.CAN-19-2296.
     PubMed     Abstract available
     
     
     
149. AUNG A, Kumar V, Theprungsirikul J, Davey SK, et al
     An engineered tumor-on-a-chip device with breast cancer-immune cell interactions for assessing T-cell recruitment.
     Cancer Res. 2019 Nov 19. pii: 0008-5472.CAN-19-0342.
     PubMed     Abstract available
     
     
     
150. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
     Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
     Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
     PubMed     Abstract available
     
     
     
151. UMEH-GARCIA M, Simion C, Ho PY, Batra N, et al
     A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells.
     Cancer Res. 2019 Nov 6. pii: 0008-5472.CAN-19-0656.
     PubMed     Abstract available
     
     
     October 2019
152. BARBIE TU, Ritter JL, Zhu Z, Thai TC, et al
     Phosphorylation of RAB7 by TBK1/IKKepsilon Regulates Innate Immune Signaling in Triple Negative Breast Cancer.
     Cancer Res. 2019 Oct 29. pii: 0008-5472.CAN-19-1310.
     PubMed     Abstract available
     
     
     
153. JIA M, Andreassen T, Jensen L, Bathen TF, et al
     Editor's Note: Estrogen Receptor alpha Promotes Breast Cancer by Reprogramming Choline Metabolism.
     Cancer Res. 2019;79:5458.
     PubMed    
     
     
     
154. KEHM RD, Genkinger JM, MacInnis RJ, John EM, et al
     Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: a cohort study of women selected for familial and genetic risk.
     Cancer Res. 2019 Oct 2. pii: 0008-5472.CAN-19-1847.
     PubMed     Abstract available
     
     
     September 2019
155. HATA T, Rajabi H, Takahashi H, Yasumizu Y, et al
     MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.
     Cancer Res. 2019 Sep 13. pii: 0008-5472.CAN-19-1034.
     PubMed     Abstract available
     
     
     
156. HERMANO E, Goldberg R, Rubinstein AM, Sonnenblick A, et al
     Heparanase accelerates obesity-associated breast cancer progression.
     Cancer Res. 2019 Sep 3. pii: 0008-5472.CAN-18-4058.
     PubMed     Abstract available
     
     
     August 2019
157. YANG T, Ren C, Lu C, Qiao P, et al
     Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer.
     Cancer Res. 2019 Aug 13. pii: 0008-5472.CAN-19-0063.
     PubMed     Abstract available
     
     
     
158. PEIFFER DS, Wyatt D, Zlobin A, Piracha A, et al
     DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy.
     Cancer Res. 2019 Aug 6. pii: 0008-5472.CAN-19-1110.
     PubMed     Abstract available
     
     
     July 2019
159. WANG MY, Chen PS, Prakash E, Hsu HC, et al
     Editor's Note: Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1.
     Cancer Res. 2019;79:3792.
     PubMed    
     
     
     
160. INGMAN WV
     The Gut Microbiome: A New Player in Breast Cancer Metastasis.
     Cancer Res. 2019;79:3539-3541.
     PubMed     Abstract available
     
     
     
161. YE S, Ding YF, Jia WH, Liu XL, et al
     SET domain-containing protein 4 epigenetically controls breast cancer stem cell quiescence.
     Cancer Res. 2019 Jul 15. pii: 0008-5472.CAN-19-1084.
     PubMed     Abstract available
     
     
     
162. SACHDEVA R, Wu M, Smiljanic S, Kaskun O, et al
     ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
     Cancer Res. 2019 Jul 10. pii: 0008-5472.CAN-18-1357.
     PubMed     Abstract available
     
     
     
163. PRIETO-VILA M, Usuba W, Takahashi RU, Shimomura I, et al
     Single-cell Analysis Reveals a Preexisting Drug-Resistant Subpopulation in the Luminal Breast Cancer Subtype.
     Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-19-0122.
     PubMed     Abstract available
     
     
     
164. HE L, Yuan L, Sun Y, Wang P, et al
     Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression.
     Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-19-0012.
     PubMed     Abstract available
     
     
     June 2019
165. ACHARYA S, Yao J, Li P, Zhang C, et al
     Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer.
     Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3803.
     PubMed     Abstract available
     
     
     
166. PELUFFO G, Subedee A, Harper NW, Kingston N, et al
     EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis.
     Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3264.
     PubMed     Abstract available
     
     
     
167. GOMEZ-MIRAGAYA J, Diaz-Navarro A, Tonda R, Beltran S, et al
     Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
     Cancer Res. 2019 Jun 18. pii: 0008-5472.CAN-18-3835.
     PubMed     Abstract available
     
     
     
168. JARDIM-PERASSI BV, Huang S, Dominguez-Viqueira W, Poleszczuk J, et al
     Multiparametric MRI and co-registered histology identify tumor habitats in breast cancer mouse models.
     Cancer Res. 2019 Jun 11. pii: 0008-5472.CAN-19-0213.
     PubMed     Abstract available
     
     
     
169. MANSOUR M, Haupt S, Chan AL, Godde N, et al
     Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.
     Cancer Res. 2019;79:3008.
     PubMed    
     
     
     May 2019
170. LAI X, Geier OM, Fleischer T, Garred O, et al
     Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data.
     Cancer Res. 2019 May 22. pii: 0008-5472.CAN-18-1804.
     PubMed     Abstract available
     
     
     
171. SHEN M, Dong C, Ruan X, Yan W, et al
     Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2.
     Cancer Res. 2019 May 22. pii: 0008-5472.CAN-18-4055.
     PubMed     Abstract available
     
     
     
172. PRABAKARAN I, Wu Z, Lee C, Tong B, et al
     Gaussian mixture models for probabilistic classification of breast cancer.
     Cancer Res. 2019 May 21. pii: 0008-5472.CAN-19-0573.
     PubMed     Abstract available
     
     
     
173. RON A, Dean-Ben XL, Gottschalk S, Razansky D, et al
     Volumetric optoacoustic imaging unveils high-resolution patterns of acute and cyclic hypoxia in a murine model of breast cancer.
     Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3769.
     PubMed     Abstract available
     
     
     
174. BUCHTA ROSEAN C, Bostic RR, Ferey JCM, Feng TY, et al
     Pre-existing commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer.
     Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-3464.
     PubMed     Abstract available
     
     
     
175. STEWART RL, Updike KL, Factor RE, Henry NL, et al
     A multigene assay determines risk of recurrence in patients with triple-negative breast cancer.
     Cancer Res. 2019 May 2. pii: 0008-5472.CAN-18-3014.
     PubMed     Abstract available
     
     
     
176. VALETA-MAGARA A, Gadi A, Volta V, Walters B, et al
     Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network.
     Cancer Res. 2019 May 1. pii: 0008-5472.CAN-17-2158.
     PubMed     Abstract available
     
     
     
177. MCANDREWS KM, Kalluri R
     Nischarin Regulates Secretion of Exosomes and Cancer Progression.
     Cancer Res. 2019;79:2099-2101.
     PubMed     Abstract available
     
     
     April 2019
178. LIU LM, Sun WZ, Fan XZ, Xu YL, et al
     Methylation of C/EBPalpha by PRMT1 inhibits its tumor suppressive function in breast cancer.
     Cancer Res. 2019 Apr 23. pii: 0008-5472.CAN-18-3211.
     PubMed     Abstract available
     
     
     
179. TRUONG DD, Kratz A, Park JG, Barrientos ES, et al
     A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells.
     Cancer Res. 2019 Apr 16. pii: 0008-5472.CAN-18-2293.
     PubMed     Abstract available
     
     
     
180. SHARMA D
     Quest for Tangible Biomarkers for Triple-Negative Breast Cancer.
     Cancer Res. 2019;79:1746-1748.
     PubMed     Abstract available
     
     
     
181. COLOMBO MP, Lecis D
     When Failure Is Worse Than Giving Up: The Case of CTL.
     Cancer Res. 2019;79:1753-1755.
     PubMed     Abstract available
     
     
     
182. ZHANG H, Zhang N, Liu Y, Su P, et al
     Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer.
     Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-3418.
     PubMed     Abstract available
     
     
     
183. JUNG SY, Papp JC, Sobel EM, Yu H, et al
     Breast cancer risk and insulin resistance: post genome-wide gene-environment interaction study using a random survival forest.
     Cancer Res. 2019 Apr 1. pii: 0008-5472.CAN-18-3688.
     PubMed     Abstract available
     
     
     March 2019
184. YIN T, Zhao ZB, Guo J, Wang T, et al
     Aurora-A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer.
     Cancer Res. 2019 Mar 22. pii: 0008-5472.CAN-18-3397.
     PubMed     Abstract available
     
     
     
185. COX OT, Edmunds SJ, Simon-Keller K, Li B, et al
     PDLIM2 is a marker of adhesion and beta-catenin activity in triple-negative breast cancer.
     Cancer Res. 2019 Mar 18. pii: 0008-5472.CAN-18-2787.
     PubMed     Abstract available
     
     
     
186. BIRGE RB, Kasikara C, Davra V, Calianese D, et al
     Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer.
     Cancer Res. 2019 Mar 15. pii: 0008-5472.CAN-18-2614.
     PubMed     Abstract available
     
     
     
187. MADAK-ERDOGAN Z, Band S, Zhao YC, Smith BP, et al
     Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling.
     Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2849.
     PubMed     Abstract available
     
     
     
188. YAMAMOTO M, Jin C, Hata T, Yasumizu Y, et al
     MUC1-C INTEGRATES CHROMATIN REMODELING AND PARP1 ACTIVITY IN THE DNA DAMAGE RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS.
     Cancer Res. 2019 Mar 1. pii: 0008-5472.CAN-18-3259.
     PubMed     Abstract available
     
     
     February 2019
189. BHOLA NE, Jansen VM, Bafna S, Giltnane JM, et al
     Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.
     Cancer Res. 2019;79:876.
     PubMed    
     
     
     
190. BHOLA NE, Jansen VM, Koch JP, Li H, et al
     Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
     Cancer Res. 2019;79:875.
     PubMed    
     
     
     
191. JANSEN VM, Bhola NE, Bauer JA, Formisano L, et al
     Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
     Cancer Res. 2019;79:874.
     PubMed    
     
     
     
192. HANKER AB, Estrada MV, Bianchini G, Moore PD, et al
     Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
     Cancer Res. 2019;79:873.
     PubMed    
     
     
     
193. HONG BS, Ryu HS, Kim N, Kim J, et al
     Tumor suppressor microRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer.
     Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-0891.
     PubMed     Abstract available
     
     
     
194. SHINDE A, Hardy SD, Kim D, Akhand SS, et al
     Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer.
     Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2636.
     PubMed     Abstract available
     
     
     January 2019
195. STEIN RG, Ebert S, Schlahsa L, Scholz CJ, et al
     Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.
     Cancer Res. 2019 Jan 28. pii: 0008-5472.CAN-18-0387.
     PubMed     Abstract available
     
     
     
196. MAZIVEYI M, Dong S, Baranwal S, Mehrnezhad A, et al
     Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and tumor growth.
     Cancer Res. 2019 Jan 11. pii: 0008-5472.CAN-18-0842.
     PubMed     Abstract available
     
     
     
197. KHAWALED S, Suh SS, Abdeen SK, Monin J, et al
     WWOX inhibits metastasis of triple-negative breast cancer cells via modulation of microRNAs.
     Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-0614.
     PubMed     Abstract available
     
     
     
198. XIANG Y, Yan K, Zheng Q, Ke H, et al
     Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
     Cancer Res. 2019;79:86-98.
     PubMed     Abstract available
     
     
     
199. BAO J, Di Lorenzo A, Lin K, Lu Y, et al
     Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases.
     Cancer Res. 2019;79:21-32.
     PubMed     Abstract available
     
     
     December 2018
200. YANG F, Takagaki Y, Yoshitomi Y, Ikeda T, et al
     Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis.
     Cancer Res. 2018 Dec 24. pii: 0008-5472.CAN-18-0620.
     PubMed     Abstract available
     
     
     
201. EL AYACHI I, Fatima I, Wend P, Alva-Ornelas JA, et al
     The WNT10B network is associated with survival and metastases in chemoresistant triple-negative breast cancer.
     Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-1069.
     PubMed     Abstract available
     
     
     November 2018
202. NILCHIAN A, Johansson J, Ghalali A, Travica Asanin S, et al
     CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
     Cancer Res. 2018 Nov 1. pii: 0008-5472.CAN-18-1742.
     PubMed     Abstract available
     
     
     
203. LI J, Ugalde-Morales E, Wen WX, Decker B, et al
     Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.
     Cancer Res. 2018;78:6329-6338.
     PubMed     Abstract available
     
     
     October 2018
204. 
     Correction: Absence of the Full-Length Breast Cancer-Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members.
     Cancer Res. 2018;78:6025.
     PubMed    
     
     
     
205. WANG Z, Grosskurth SE, Cheung T, Petteruti P, et al
     Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer.
     Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-1362.
     PubMed     Abstract available
     
     
     
206. ALI R, Al-Kawaz A, Toss MS, Green AR, et al
     Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
     Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0633.
     PubMed     Abstract available
     
     
     
207. 
     Retraction: Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.
     Cancer Res. 2018;78:5719.
     PubMed    
     
     
     September 2018
208. ELDER AM, Tamburini BA, Crump LS, Black SA, et al
     Semaphorin 7A promotes macrophage-mediated lymphatic remodeling during postpartum mammary gland involution and in breast cancer.
     Cancer Res. 2018 Sep 25. pii: 0008-5472.CAN-18-1642.
     PubMed     Abstract available
     
     
     
209. CHEN C, Okita Y, Watanabe Y, Abe F, et al
     Glycoprotein nmb is exposed on the surface of dormant breast cancer cells and induces stem cell-like properties.
     Cancer Res. 2018 Sep 17. pii: 0008-5472.CAN-18-0599.
     PubMed     Abstract available
     
     
     
210. DINARELLO CA
     An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.
     Cancer Res. 2018;78:5200-5202.
     PubMed     Abstract available
     
     
     
211. GAUDET MM, Gierach GL, Carter BD, Luo J, et al
     Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype.
     Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-18-0502.
     PubMed     Abstract available
     
     
     
212. 
     Retraction: Zerumbone Abolishes RANKL-Induced NF-kappaB Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice.
     Cancer Res. 2018;78:5186.
     PubMed    
     
     
     August 2018
213. HUANG F, Shi Q, Li Y, Xu L, et al
     HER2/EGFR-AKT signaling switches TGF-beta from inhibiting cell proliferation to promoting cell migration in breast cancer.
     Cancer Res. 2018 Aug 31. pii: 0008-5472.CAN-18-0136.
     PubMed     Abstract available
     
     
     
214. YANOVICH G, Agmon H, Harel M, Sonnenblick A, et al
     Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification.
     Cancer Res. 2018 Aug 28. pii: 0008-5472.CAN-18-1079.
     PubMed     Abstract available
     
     
     
215. AL ABSI A, Wurzer H, Guerin CL, Hoffmann C, et al
     Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer-mediated cytotoxicity.
     Cancer Res. 2018 Aug 13. pii: 0008-5472.CAN-18-0441.
     PubMed     Abstract available
     
     
     
216. MURALI B, Ren Q, Luo X, Faget DV, et al
     Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss.
     Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-18-0234.
     PubMed     Abstract available
     
     
     
217. ZHANG FL, Cao JL, Xie HY, Sun R, et al
     Cancer-associated MORC2 mutant M276I regulates an hnRNPM-mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer.
     Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-17-1394.
     PubMed     Abstract available
     
     
     
218. ZHOU R, Bagga P, Nath K, Hariharan H, et al
     Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging (GluCEST MRI) detects glutaminase inhibition in a mouse model of triple-negative breast cancer.
     Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3988.
     PubMed     Abstract available
     
     
     July 2018
219. UBELLACKER JM, Baryawno N, Severe N, DeCristo MJ, et al
     Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer.
     Cancer Res. 2018 Jul 31. pii: 0008-5472.CAN-18-0548.
     PubMed     Abstract available
     
     
     
220. CROSET M, Pantano F, Kan CWS, Bonnelye E, et al
     MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes.
     Cancer Res. 2018 Jul 24. pii: 0008-5472.CAN-17-3058.
     PubMed     Abstract available
     
     
     
221. XING F, Liu Y, Wu SY, Wu K, et al
     Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
     Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-1102.
     PubMed     Abstract available
     
     
     
222. WU TC, Xu K, Martinek J, Young RR, et al
     IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer.
     Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-18-0413.
     PubMed     Abstract available
     
     
     
223. XING Z, Zhang Y, Liang K, Yan L, et al
     Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer.
     Cancer Res. 2018 Jul 2. pii: 0008-5472.CAN-17-0385.
     PubMed     Abstract available
     
     
     June 2018
224. ZHANG W, Wu M, Chong QY, Zhang M, et al
     Loss of estrogen-regulated MIR135A1 at 3p21.1 promotes tamoxifen resistance in breast cancer.
     Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-18-0069.
     PubMed     Abstract available
     
     
     
225. SUN R, Xie HY, Qian JX, Huang YN, et al
     FBXO22 possesses both pro-tumorigenic and anti-metastatic roles in breast cancer progression.
     Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3647.
     PubMed     Abstract available
     
     
     
226. IM YK, Najyb O, Gravel SP, McGuirk S, et al
     Interplay between ShcA signaling and PGC-1alpha triggers targetable metabolic vulnerabilities in breast cancer.
     Cancer Res. 2018 Jun 21. pii: 0008-5472.CAN-17-3696.
     PubMed     Abstract available
     
     
     
227. 
     Correction: TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
     Cancer Res. 2018;78:3403.
     PubMed    
     
     
     
228. HE JP, Hou PP, Chen QT, Wang WJ, et al
     Flightless-I blocks p62-mediated recognition of LC3 to impede selective autophagy and promote breast cancer progression.
     Cancer Res. 2018 Jun 13. pii: 0008-5472.CAN-17-3835.
     PubMed     Abstract available
     
     
     
229. GOOD CR, Panjarian S, Kelly AD, Madzo J, et al
     TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer.
     Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-2082.
     PubMed     Abstract available
     
     
     
230. LU H, Tran L, Park Y, Chen I, et al
     Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF-1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
     Cancer Res. 2018 Jun 7. pii: 0008-5472.CAN-18-0270.
     PubMed     Abstract available
     
     
     May 2018
231. JASTRZEBSKI K, Thijssen B, Kluin RJ, de Lint K, et al
     Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.
     Cancer Res. 2018 May 29. pii: 0008-5472.CAN-17-2698.
     PubMed     Abstract available
     
     
     
232. MATSUNAGA N, Ogino T, Hara Y, Tanaka T, et al
     Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the anti-tumor effects of aldehyde dehydrogenase.
     Cancer Res. 2018 May 7. pii: 0008-5472.CAN-17-4034.
     PubMed     Abstract available
     
     
     April 2018
233. ZHENG YZ, Xue MZ, Shen HJ, Li XG, et al
     PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.
     Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3514.
     PubMed     Abstract available
     
     
     
234. AVANZATO D, Pupo E, Ducano N, Isella C, et al
     High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis.
     Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3018.
     PubMed     Abstract available
     
     
     March 2018
235. WANG LH, Tseng CW, Kuo WH, Chan SH, et al
     Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
     Cancer Res. 2018 Mar 29. pii: 0008-5472.CAN-17-2906.
     PubMed     Abstract available
     
     
     
236. ZHANG B, Chen MY, Sheng YJ, Zhuo XB, et al
     A large-scale, exome-wide association study of Han Chinese women identifies three novel loci predisposing to breast cancer.
     Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-1721.
     PubMed     Abstract available
     
     
     
237. REN D, Zhu X, Kong R, Zhao Z, et al
     Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
     Cancer Res. 2018 Mar 22. pii: 0008-5472.CAN-17-2994.
     PubMed     Abstract available
     
     
     
238. HOU J, Williams J, Botvinick E, Potma E, et al
     Visualization of breast cancer metabolism using multimodal non-linear optical microscopy of cellular lipids and redox state.
     Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2618.
     PubMed     Abstract available
     
     
     
239. LUAN H, Mohapatra B, Bielecki TA, Mushtaq I, et al
     Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program.
     Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-16-2140.
     PubMed     Abstract available
     
     
     February 2018
240. HORNSVELD M, Smits LM, Meerlo M, van Amersfoort M, et al
     FOXO transcription factors both suppress and support breast cancer progression.
     Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2511.
     PubMed     Abstract available
     
     
     
241. HAO J, Yan F, Zhang Y, Triplett A, et al
     Expression of adipocyte/macrophage fatty acid binding protein in tumor associated macrophages promotes breast cancer progression.
     Cancer Res. 2018 Feb 6. pii: 0008-5472.CAN-17-2465.
     PubMed     Abstract available
     
     
     January 2018
242. WERFEL TA, Wang S, Jackson MA, Kavanaugh TE, et al
     Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival.
     Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-2388.
     PubMed     Abstract available
     
     
     
243. JIAO X, Velasco-Velazquez MA, Wang M, Li Z, et al
     CCR5 governs DNA damage and breast cancer stem cell expansion.
     Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0915.
     PubMed     Abstract available
     
     
     
244. LUDWIK KA, McDonald OG, Brenin DR, Lannigan DA, et al
     ERalpha-mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-2063.
     PubMed     Abstract available
     
     
     
245. ZHANG Y, Manjunath M, Zhang S, Chasman D, et al
     Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-3486.
     PubMed     Abstract available
     
     
     
246. NAGAHASHI M, Yamada A, Katsuta E, Aoyagi T, et al
     Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1423.
     PubMed     Abstract available
     
     
     
247. EVANS MK, Brown MC, Geradts J, Bao X, et al
     XIAP regulation by MNK links MAPK and NFkappaB signaling to determine an aggressive breast cancer phenotype.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1667.
     PubMed     Abstract available
     
     
     
248. SAHA M, Kumar S, Bukhari S, Balaji SA, et al
     AMPK-AKT double negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation.
     Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2090.
     PubMed     Abstract available
     
     
     
249. SARVI S, Patel H, Li J, Dodd GL, et al
     Kindlin-1 promotes pulmonary breast cancer metastasis.
     Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-1518.
     PubMed     Abstract available
     
     
     
250. NOUGAREDE A, Popgeorgiev N, Kassem L, Omarjee S, et al
     Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.
     Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-0846.
     PubMed     Abstract available
     
     
     December 2017
251. MAEDA T, Hiraki M, Jin C, Rajabi H, et al
     MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
     Cancer Res. 2017 Dec 20. pii: 0008-5472.CAN-17-1636.
     PubMed     Abstract available
     
     
     
252. EKAMBARAM P, Lee JL, Hubel NE, Hu D, et al
     The CARMA3-Bcl10-MALT1 Signalosome Drives NF-kappaB Activation and Promotes Aggressiveness in Angiotensin II Receptor-positive Breast Cancer.
     Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-1089.
     PubMed     Abstract available
     
     
     
253. SHARMA C, Wang HX, Li Q, Knoblich K, et al
     Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence.
     Cancer Res. 2017;77:6880-6890.
     PubMed     Abstract available
     
     
     
254. PAOLETTI C, Cani AK, Larios JM, Hovelson DH, et al
     Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.
     Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-2686.
     PubMed     Abstract available
     
     
     
255. TELONIS AG, Rigoutsos I
     Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer.
     Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1947.
     PubMed     Abstract available
     
     
     
256. EL-SHENNAWY L, Dubrovskyi O, Kastrati I, Danes JM, et al
     Coactivation of estrogen receptor and IKK-beta induces a dormant metastatic phenotype in ER-positive breast cancer.
     Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1686.
     PubMed     Abstract available
     
     
     
257. WU Y, Zhang Z, Cenciarini ME, Proietti CJ, et al
     Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis.
     Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-1327.
     PubMed     Abstract available
     
     
     November 2017
258. HOU P, Li L, Chen F, Chen Y, et al
     PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
     PubMed     Abstract available
     
     
     
259. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
     Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
     PubMed     Abstract available
     
     
     
260. BYRD TT, Fousek K, Pignata A, Szot C, et al
     TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
     Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
     PubMed     Abstract available
     
     
     
261. PAJIC M, Froio D, Daly S, Doculara L, et al
     miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-16-3105.
     PubMed     Abstract available
     
     
     
262. CAMPBELL TM, Castro MA, deOliveira KG, Ponder BA, et al
     ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 signalling to modulate estrogen responsiveness in breast cancer.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1153.
     PubMed     Abstract available
     
     
     
263. CAREY JP, Karakas C, Bui T, Chen X, et al
     Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1494.
     PubMed     Abstract available
     
     
     
264. PALMER JR, Castro-Webb N, Bertrand K, Bethea TN, et al
     Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.
     Cancer Res. 2017;77:6462-6469.
     PubMed     Abstract available
     
     
     October 2017
265. PATIN EC, Soulard D, Fleury S, Hassane M, et al
     Type I IFN receptor signalling controls IL-7-dependent accumulation and activity of protumoral IL-17A-producing gammadeltaT cells in breast cancer.
     Cancer Res. 2017 Oct 25. pii: canres.1416.2017.
     PubMed     Abstract available
     
     
     
266. TURCOTTE M, Allard D, Mittal D, Bareche Y, et al
     CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
     Cancer Res. 2017;77:5652-5663.
     PubMed     Abstract available
     
     
     September 2017
267. ISHIHARA S, Inman DR, Li WJ, Ponik SM, et al
     Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells.
     Cancer Res. 2017 Sep 28. pii: canres.0569.2017.
     PubMed     Abstract available
     
     
     
268. YANG A, Qin S, Schulte BA, Ethier SP, et al
     MYC Inhibition depletes cancer stem-like cells in triple-negative breast cancer.
     Cancer Res. 2017 Sep 26. pii: canres.3452.2016.
     PubMed     Abstract available
     
     
     
269. TEO ZL, Versaci S, Dushyanthen S, Caramia F, et al
     Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple negative breast cancer.
     Cancer Res. 2017 Sep 25. pii: canres.2210.2017.
     PubMed     Abstract available
     
     
     
270. CHEN L, Chubak J, Boudreau DM, Barlow WE, et al
     Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: A SEER-Medicare analysis.
     Cancer Res. 2017 Sep 21. pii: canres.0687.2017.
     PubMed     Abstract available
     
     
     
271. DAVIES H, Morganella S, Purdie CA, Jang SJ, et al
     Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.
     Cancer Res. 2017;77:4755-4762.
     PubMed     Abstract available
     
     
     
272. KATZENELLENBOGEN BS, Zhao Y, Laws MJ, Sanabria Guillen V, et al
     Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors.
     Cancer Res. 2017 Sep 13. pii: canres.1265.2017.
     PubMed     Abstract available
     
     
     
273. DETHLEFSEN C, Hansen LS, Lillelund C, Andersen C, et al
     Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development.
     Cancer Res. 2017 Sep 8. doi: 10.1158/0008-5472.CAN-16-3125.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: